Every letter we have printed

Supply is a reason in this market that has no analogue in the trial literature. A source that becomes unavailable ends an arrangement as effectively as an adverse effect, and no clinical taxonomy has a category for it.

The industry-funded and investigator-initiated withdrawal studies in this area differ systematically in follow-up length. That is a fact about funding rather than about biology, and it should appear in any summary table.

The trial designs answer a question about the drug and the reader has a question about themselves. A mean regain curve tells an individual very little about their own trajectory, and the variance around those means is rarely printed with the same prominence.

A note of thanks from a long-standing reader who has never written before. The consistency across thirty issues is the thing worth remarking on, and consistency never gets a letter.

A small format complaint. Reports that state a mass to four decimal places and an error in parts per million, without stating the mass at which the calibration was performed, are precise about the wrong thing. Precision presented without its provenance reads as authority and is not.

The value I most want on an identity report is the theoretical mass the analyst calculated, printed beside the observed one. Half the reports I receive give only the observed figure, which requires the reader to redo the arithmetic and to guess which charge state and which counter-ion the analyst assumed.

You give the glutamine-to-lysine difference as 0.036 daltons and say it needs an orbital trap. In practice you also need the two species to be chromatographically separated or present in a sensible ratio, because at one per cent of the parent intensity the minor peak sits on the shoulder of the isotope envelope regardless of resolving power.

You write that leucine and isoleucine cannot be distinguished by tandem mass spectrometry. That is too absolute. Side-chain fragmentation under high-energy conditions produces diagnostic w and d ions, and the discrimination has been demonstrated repeatedly.

A short note of thanks. I sent this article to two people who needed it and neither has argued with me since.

A certificate for a molecule is not a certificate for a vial. Where a supplier publishes one document per product rather than one per lot, the document is marketing with a chromatogram attached, however genuine the underlying determination was.

Sample quantity is a provenance question in disguise. A determination performed on the whole vial and one performed on a few milligrams taken from the top of a settled cake are not equivalent, and neither the amount nor the sampling method appears on any certificate I have collected.

We learned this the expensive way. A co-eluting truncation two residues short sat under our main peak for months, invisible on a unit-resolution instrument and obvious the first time the sample went onto a better one. Nobody had done anything wrong; the tool simply could not see it.

Isotope envelopes are where resolution becomes visible to a non-specialist. At low resolving power a peptide is a hump; at high resolving power it is a comb whose spacing tells you the charge state directly. If the report shows a hump, the instrument has not answered the question you paid it to answer.

A modest suggestion for the reference desk: a table of every composition substudy with its sample size, method, duration and population beside the headline ratio. It would settle a great many arguments by making the basis of each number visible at once.

Age and baseline muscularity change the answer more than most sources admit. A finding averaged across a trial population is not a prediction about a person at either end of that distribution, and popular summaries convert averages into individual expectations almost automatically.

Comparing substudies across trials requires the scanner model and software version, because absolute values differ between them. Almost nobody who compares them checks, and the manufacturers are quite clear that they should.

I have read your protein tables twice and I still cannot work out what I should eat. I appreciate that this is the honest position but it is not a useful one for a person in a supermarket.

Tapering is described in the community literature with a confidence the published evidence does not support. There is no trial that compares a taper against an abrupt stop in this class, and the absence should be stated wherever the practice is discussed.

Where a reason is recorded by a clinician rather than by the person, the categories reflect what the clinician was listening for. That is not a criticism of clinicians; it is a property of any coded record, and it is rarely acknowledged in the resulting statistics.

The clinical trials that inform this discussion ran for a fixed period and stopped. Every statement about maintenance beyond that horizon is extrapolation, and the confidence with which extrapolations are stated in general discussion is not warranted by their source.

Reasons are ranked in most reporting and the ranking is a function of the category list. Change the list and the ranking changes, which means the headline finding of most of these surveys is a property of their questionnaire.

The word maintenance carries an assumption that the maintained state is stable. Everything in the published record suggests it is a position held against a gradient, and the vocabulary of maintenance makes the effort involved invisible to people planning around it.

Adherence typically falls over the course of a long trial, and a falling adherence curve will produce a flattening outcome curve without any change in response. The two are rarely plotted together.

Escalating in response to a plateau is discussed as though the relationship between exposure and effect were linear beyond the studied range. It is not, in any published dose-response data I have seen, and the curve flattens there too.

The point I would press is documentation. Whatever schedule is followed, writing down the dose, the date and what happened turns an anecdote into a small dataset. Most of the confusion I hear about comes from people who cannot reconstruct what they did.

Where a trial permitted a delay in escalation, the proportion who used it is reported in some papers and is an interesting number in its own right. It is closer to real practice than the nominal schedule.

Duration of the published trials is short relative to the question. Whether a plateau at month twelve is stable at month thirty-six is a question no study in this class has answered, and it is answered confidently in general discussion.

Maintenance after a plateau is where the evidence is thinnest and where most people spend most of their time. That imbalance between what is studied and what is lived is the strongest argument for the withdrawal literature you covered separately.

Dose-response data in this class flattens well before the top of the studied range on most endpoints, which is the actual argument against escalation. It is a stronger argument than the one usually made and it comes from published curves.

Trial protocols specify what to do after a missed administration, and those instructions are the closest thing to evidence-based guidance available. They are freely readable in the supplementary materials and almost never quoted.

A step from one dose to the next is a proportional change and the proportion shrinks as the doses rise. Doubling early in a schedule is a much larger relative change than the same absolute increment later, and tolerability tracks the proportion rather than the milligrams.

Panels sold direct to consumers are assembled for marketing as much as for clinical use, which is why they are long. A shorter panel repeated on a schedule is more informative than a long one taken once.

Deciding in advance what would change a decision is the discipline missing from most self-arranged testing. A test that cannot change anything is a purchase rather than a measurement.

Receptor distribution maps come largely from tissue studies with antibodies of variable specificity, and several widely reproduced maps rest on reagents that were later questioned. The provenance of a distribution map matters as much as its content.

Receptor expression in cardiac tissue is limited and much of the cardiovascular effect is likely indirect. I would rather see that stated as the current reading of the evidence than see the outcome data described as though the mechanism were established.

Concentration matters for solution stability and it is chosen by the person reconstituting rather than by anybody who has studied it. A dilute preparation and a concentrated one are two different experiments, and both are described by the same anecdote.

In-use stability is a property of a preparation and everything published is about a powder. The moment a vial is reconstituted it becomes a different material with a different shelf life, and the certificate that came with it has nothing to say about that.

Phase-change packs are worth the modest extra cost over water ice and almost nobody asks for them. They hold a narrower band for longer and they do not produce the initial sub-zero shock that a freshly frozen gel pack in direct contact with a vial can.

I have been buying research peptides for six years and I did not know that the label mass referred to fill mass rather than peptide mass. I have recalculated three years of notes this week. Thank you, I think.

Your table gives vial H at 81% content with 98.9% stated purity. Those two numbers together imply nearly a fifth of the vial is something other than peptide and yet almost none of it shows up chromatographically. Can you explain the mechanism rather than just reporting it?